Spots Global Cancer Trial Database for gastroesophageal cancer
Every month we try and update this database with for gastroesophageal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG) | NCT05431738 | Stent Migration GastroEsophagea... | Gastroesophagea... | 18 Years - 91 Years | Société Française d'Endoscopie Digestive | |
| Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer | NCT00439608 | Esophageal Canc... Gastric Cancer | Cetuximab,Pacli... | 18 Years - | Brown University | |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | NCT01145404 | GastroEsophagea... | Lapatinib Lapatinib plus ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | NCT03829436 | Hepatocellular ... Metastatic Cast... Renal Cell Carc... Non-small Cell ... Colorectal Canc... Squamous Cell C... Triple-Negative... Urothelial Carc... Cholangiocarcin... GastroEsophagea... Pancreatic Canc... Sarcoma | Part 1 TPST-112... Part 2 TPST-112... Part 3 TPST-112... Part 4 TPST-112... | 18 Years - | Tempest Therapeutics | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | NCT03818997 | Esophageal Canc... Biliary Tract C... GastroEsophagea... Hepatobiliary N... | DKN-01 Atezolizumab Paclitaxel | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | NCT03044613 | Gastric Cancer Esophageal Canc... GastroEsophagea... | Nivolumab Relatlimab Carboplatin Paclitaxel Radiation | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Early IntraVenous Administration of Nutritional Support | NCT03949907 | Cancer of Stoma... GastroEsophagea... | Nutritional cou... Early supplemen... | 18 Years - | IRCCS Policlinico S. Matteo | |
| Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen | NCT01365130 | Esophageal Gastrooesophage... Gastric Cancer | jevtana | 18 Years - | Brown University | |
| Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy | NCT03613142 | Gastric Cancer GastroEsophagea... | Double tract an... Esophagogastros... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | NCT03125200 | Breast Cancer Non Small Cell ... GastroEsophagea... Bladder Cancer | ADCT-502 | 18 Years - | ADC Therapeutics S.A. | |
| Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer | NCT04688801 | Esophageal Canc... Gastroesophagea... Immunotherapy Adjuvant | Chemotherapy Dr... Immunotherapy | 25 Years - 80 Years | The Second Hospital of Shandong University | |
| Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America | NCT05924789 | Gastric Cancer GastroEsophagea... Pancreatic Canc... | Observational s... | 18 Years - | Latin American Cooperative Oncology Group | |
| PREoperativ Study of Exercise Training | NCT03490565 | GastroEsophagea... | Exercise traini... | 18 Years - 85 Years | Rigshospitalet, Denmark | |
| A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | NCT03720678 | GastroEsophagea... Colorectal Canc... | etrumadenant mFOLFOX | 18 Years - | Arcus Biosciences, Inc. | |
| Metronomic Chemotherapy in Advanced Gastric Cancer | NCT02855788 | Metastatic Gast... Locally Advance... | Paclitaxel 60mg... | 18 Years - 70 Years | Huashan Hospital | |
| A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies | NCT03321630 | GastroEsophagea... Gastric Cancer | Lenvatinib Pembrolizumab | 18 Years - 100 Years | NYU Langone Health | |
| Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | NCT05379972 | Gastric Cancer GastroEsophagea... | Pembrolizumab Olaparib Stereotactic Bo... | 18 Years - 100 Years | University of Colorado, Denver | |
| Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma | NCT04069273 | Gastric Cancer GastroEsophagea... Adenocarcinoma | Pembrolizumab M... Ramucirumab Paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | NCT05427487 | Colorectal Canc... Gastroesophagea... Ovarian Cancer | IVX037 | 18 Years - 85 Years | ImmVirx Pty Ltd | |
| The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES) | NCT06138223 | GastroEsophagea... Incurable Disea... | Exercise interv... Nutrition inter... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | NCT03775850 | Colorectal Canc... Triple Negative... Non Small Cell ... Bladder Cancer GastroEsophagea... Renal Cell Carc... MSI-H | EDP1503 Pembrolizumab | 18 Years - | Evelo Biosciences, Inc. | |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | NCT01145404 | GastroEsophagea... | Lapatinib Lapatinib plus ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | NCT03775850 | Colorectal Canc... Triple Negative... Non Small Cell ... Bladder Cancer GastroEsophagea... Renal Cell Carc... MSI-H | EDP1503 Pembrolizumab | 18 Years - | Evelo Biosciences, Inc. | |
| Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | NCT02853474 | Gastric Cancer Pancreas Cancer Bile Duct Cance... Gastroesophagea... Esophageal Canc... | Early Palliativ... EORTC-QLQ-C30 q... HADS score | 18 Years - | Centre Oscar Lambret | |
| A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer | NCT05338060 | GastroEsophagea... | prospective col... | 18 Years - | Inova Health Care Services | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05620134 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Melanoma Colorectal Canc... Non-small Cell ... Small-cell Lung... Urothelial Carc... Squamous Cell C... Luminal Breast ... Triple Negative... Clear Cell Rena... Papillary Renal... Gastric Adenoca... GastroEsophagea... Squamous Cell C... Pancreatic Aden... Hepatocellular ... Colorectal Aden... Epithelial Ovar... Thyroid Cancer | JK08 Pembrolizumab | 18 Years - | Salubris Biotherapeutics Inc | |
| Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | NCT03330028 | Diseases of Oes... | Dexamethasone Diphenhydramine Famotidine Mitomycin C Cisplatin Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer | NCT04688801 | Esophageal Canc... Gastroesophagea... Immunotherapy Adjuvant | Chemotherapy Dr... Immunotherapy | 25 Years - 80 Years | The Second Hospital of Shandong University | |
| Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study | NCT06241469 | Gastric Cancer GastroEsophagea... Adenocarcinoma | Sintilimab,nab-... | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America | NCT05924789 | Gastric Cancer GastroEsophagea... Pancreatic Canc... | Observational s... | 18 Years - | Latin American Cooperative Oncology Group | |
| Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT | NCT00718354 | Gastric Cancer Gastroesophagea... | Enoxaparin Standard Chemot... | 18 Years - 75 Years | Thrombosis Research Institute | |
| A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer | NCT03813784 | Gastric Cancer GastroEsophagea... | SHR-1210 Capecitabine Oxaliplatin Apatinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | NCT01145404 | GastroEsophagea... | Lapatinib Lapatinib plus ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | NCT06065371 | Gastrointestina... | Capecitabine Sacituzumab gov... | 18 Years - | Henry Ford Health System | |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | NCT03314935 | Biliary Tract C... Colorectal Canc... Endometrial Can... Gastroesophagea... Ovarian Cancer Solid Tumors | INCB001158 Oxaliplatin Leucovorin 5-Fluorouracil Gemcitabine Cisplatin Paclitaxel | 18 Years - | Incyte Corporation | |
| Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients | NCT05438940 | GastroEsophagea... | Fitbit Data Col... Nutrition Couns... Survey | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | NCT02853474 | Gastric Cancer Pancreas Cancer Bile Duct Cance... Gastroesophagea... Esophageal Canc... | Early Palliativ... EORTC-QLQ-C30 q... HADS score | 18 Years - | Centre Oscar Lambret | |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | NCT02013154 | Esophageal Neop... Adenocarcinoma ... Gastroesophagea... Squamous Cell C... Gastric Adenoca... | DKN-01 150 mg Paclitaxel Pembrolizumab DKN-01 300 mg | 18 Years - | Leap Therapeutics, Inc. | |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | NCT06356311 | Gastroesophagea... | Sacituzumab tir... Trifluridine-Ti... Irinotecan Paclitaxel Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer | NCT03647969 | Adenocarcinoma ... GastroEsophagea... | Nivolumab Ipilimumab mFOLFOX FLOT | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | NCT03165994 | Esophageal Canc... GastroEsophagea... | APX005M Radiation Thera... Paclitaxel Carboplatin Surgical resect... | 18 Years - | Apexigen America, Inc. | |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | NCT04504669 | Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ... | AZD8701 Durvalumab | 18 Years - 101 Years | AstraZeneca | |
| Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy | NCT03613142 | Gastric Cancer GastroEsophagea... | Double tract an... Esophagogastros... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer | NCT03490292 | Resectable Esop... GastroEsophagea... | Avelumab combin... Carboplatin Paclitaxel Radiation | 18 Years - | University of Wisconsin, Madison | |
| Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma | NCT05122091 | Gastric Cancer GastroEsophagea... Fruquintinib SOX | Fruquintinib + ... | 18 Years - 75 Years | Guangxi Medical University | |
| Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | NCT05427487 | Colorectal Canc... Gastroesophagea... Ovarian Cancer | IVX037 | 18 Years - 85 Years | ImmVirx Pty Ltd | |
| PRO1107 in Patients With Advanced Solid Tumors | NCT06171789 | Endometrial Can... Ovarian Cancer Triple Negative... GastroEsophagea... Non-small Cell ... Urothelial Carc... | PRO1107 | 18 Years - | ProfoundBio US Co. | |
| A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | NCT03279237 | GastroEsophagea... | Irinotecan Oxaliplatin Leucovorin 5-Fluorouracil Paclitaxel Radiation Thera... Carboplatin | 18 Years - | Massachusetts General Hospital | |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | NCT04510285 | Esophagogastric... Gastric Cancer Gastric Tumor Esophageal Canc... Esophageal Neop... Esophageal Tumo... GastroEsophagea... Gastroesophagea... Gastroesophagea... Gastroesophagea... | Trastuzumab Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) | NCT06283238 | GastroEsophagea... | Immune checkpoi... | 18 Years - | Duke University | |
| GastrOesophageal Tumor, Immune Microenvionnment (GOTIM) | NCT05644431 | GastroEsophagea... | 18 Years - | Centre Leon Berard | ||
| A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | NCT03472365 | Gastric Cancer GastroEsophagea... | SHR-1210 Capecitabine Oxaliplatin Apatinib | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | NCT04681248 | Esophageal Neop... Adenocarcinoma ... GastroEsophagea... Squamous Cell C... Gastric Adenoca... Endometrial Can... Uterine Cancer Ovarian Cancer Carcinosarcoma Gastric Cancer | DKN-01 | 18 Years - | Leap Therapeutics, Inc. | |
| Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer | NCT00042510 | Stomach Neoplas... Esophageal Neop... | Treatment group | 18 Years - | Cancer Advances Inc. | |
| Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | NCT04555304 | Gastric Cancer Gastroesophagea... | KH903 + Paclita... Placebo + Pacli... | 18 Years - | Chengdu Kanghong Biotech Co., Ltd. | |
| Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | NCT03330028 | Diseases of Oes... | Dexamethasone Diphenhydramine Famotidine Mitomycin C Cisplatin Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) | NCT06283238 | GastroEsophagea... | Immune checkpoi... | 18 Years - | Duke University | |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | NCT04510285 | Esophagogastric... Gastric Cancer Gastric Tumor Esophageal Canc... Esophageal Neop... Esophageal Tumo... GastroEsophagea... Gastroesophagea... Gastroesophagea... Gastroesophagea... | Trastuzumab Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | NCT06028737 | Gastric Cancer Stomach Cancer GastroEsophagea... Gastric Adenoca... Gastroesophagea... Advanced Gastri... Gastric Neoplas... Stomach Neoplas... Gastrointestina... Advanced Gastro... Advanced Gastri... | Docetaxel Oxaliplatin Leucovorin Fluorouracil | 18 Years - 80 Years | Ukrainian Society of Clinical Oncology | |
| PREoperativ Study of Exercise Training | NCT03490565 | GastroEsophagea... | Exercise traini... | 18 Years - 85 Years | Rigshospitalet, Denmark | |
| Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen | NCT01365130 | Esophageal Gastrooesophage... Gastric Cancer | jevtana | 18 Years - | Brown University | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00183872 | Gastric Cancer Esophageal Neop... | irinotecan, doc... | 18 Years - | University of Southern California | |
| Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy | NCT01129206 | Adenocarcinoma ... Adenocarcinomas... Recurrent Esoph... Squamous Cell C... Stage IV Esopha... | pralatrexate docetaxel fludeoxyglucose... positron emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | NCT04281576 | Gastric Cancer GastroEsophagea... | NovoTTF-100L(P) Oxaliplatin Capecitabine Trastuzumab | 18 Years - | NovoCure Ltd. | |
| Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | NCT05379972 | Gastric Cancer GastroEsophagea... | Pembrolizumab Olaparib Stereotactic Bo... | 18 Years - 100 Years | University of Colorado, Denver | |
| PRO1107 in Patients With Advanced Solid Tumors | NCT06171789 | Endometrial Can... Ovarian Cancer Triple Negative... GastroEsophagea... Non-small Cell ... Urothelial Carc... | PRO1107 | 18 Years - | ProfoundBio US Co. | |
| Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors | NCT05098132 | Advanced Solid ... Non Small Cell ... Head and Neck S... Malignant Melan... Renal Cell Carc... Cervical Cancer Microsatellite ... Gastric Cancer GastroEsophagea... Urothelial Carc... Mismatch Repair... | STK-012 Pembrolizumab | 18 Years - | Synthekine | |
| Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction | NCT00080002 | Cancer of Stoma... Gastroesophagea... | Pegamotecan | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | NCT03861793 | Advanced Solid ... | ALKS 4230 Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | NCT02274012 | HER-2 Positive ... Gastrooesophage... Esophageal Canc... | Afatinib Paclitaxel | 18 Years - | Columbia University | |
| A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers | NCT06243757 | Gastric Cancer GastroEsophagea... Gastroesophagea... | MDASI-GI | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy | NCT05717998 | Lung Non-Small ... GastroEsophagea... Esophagus Cance... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Positron Emissi... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | NCT06065371 | Gastrointestina... | Capecitabine Sacituzumab gov... | 18 Years - | Henry Ford Health System | |
| Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma | NCT00525915 | Esophageal Canc... Gastroesophagea... | 5-Fluorouracil Oxaliplatin Radiation Thera... Surgery | 18 Years - 76 Years | M.D. Anderson Cancer Center | |
| Supportive Oncology Care At Home RCT | NCT04544046 | Pancreatic Canc... GastroEsophagea... Rectal Cancer Head and Neck C... Lymphoma | Supportive Onco... Usual Care | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
